drugset / Trial / NCT05835999
Everolimus Aging Study
Phase 2
Active not recruiting
106 enrolled
University of Wisconsin, Madison
National Institute on Aging (NIA) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The objective of this project is to determine if mTORC1 inhibition by 24 weeks of daily (0.5 mg/day) or weekly (5 mg/week) everolimus can safely improve physiological and molecular hallmarks of aging in humans. Participants who are 55-80 years old and insulin resistant or prediabetic will be randomized to treatment and can expect to be on study for up to approximately 38 weeks. Participants aged 18-35 will not receive the intervention and can expect to be on study for up to approximately 8 weeks.
Timeline
- Start
- 2023-03-24
- Primary completion
- 2026-09
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 0.5 mg | Oral |
| Subject | Everolimus | Small molecule | 5 mg | Oral |